Veho and RIVR Partner to Improve E-Commerce Delivery Through AI-Powered Robots
The Tech Companies Will Start Deploying Robots This May in Austin, Texas
AUSTIN, Texas, May 27, 2025 /PRNewswire/ -- Veho, the technology company that operates the fastest-growing alternative parcel delivery platform in the U.S., and RIVR, a physical AI and robotics leader, today announced an initiative to improve e-commerce delivery experience and efficiency through the use of parcel delivery robots.
The deployment begins today in Austin, with plans to expand to additional markets later this year based upon learnings during the initial trial. The robots are not intended to replace human delivery drivers. Rather, they are intended to enable humans to deliver more parcels, faster, with less physical strain, all while maintaining the superior delivery experience for which Veho is known. The ability for humans to work with and manage robots performing deliveries may be particularly valuable in dense areas with many deliveries but limited parking.
While a human driver completes one drop-off, the wheeled-legged robot will deliver another, navigating from the delivery vehicle all the way to the customer's doorstep, placing parcels according to customer's instructions, while leveraging the Veho app to send a photo of each successful delivery. See a video of the robot here.
During the trial, a RIVR employee will accompany the robot to ensure safety and delivery quality, while Veho and RIVR team members monitor the robot to learn how it performs during real life deliveries.
"Over nine years, Veho has proven that a delivery platform and technology built for e-commerce produces better delivery experiences and economics for consumers and brands. This partnership is an exciting next step in reinventing e-commerce delivery and enabling brands to turn shipping from a cost center to a value driver," said Veho co-founder and CEO Itamar Zur. "When it comes to delivery, customers care most about its reliability, speed and cost. Working with RIVR will help us learn if pairing a human with a robot can improve delivery reliability, speed and costs, all while maintaining a great delivery and brand experience."
Veho's platform enables drivers to deliver millions of packages per month across 50 U.S. metropolitan areas, most recently launching in New York City. The technology powering Veho's network of over 30 distribution centers across the US and its app-based platform for 84,000 independent driver-partners was built entirely in-house, making Veho a partner of choice for a robotics and AI leader like RIVR.
"With the exponential rise in e-commerce, the last mile has become the most critical—and complex—link in the logistics chain. At RIVR, our mission is to put one million delivery robots into the field, leveraging General Physical AI to scale urban robotics to where it's needed most," said Marko Bjelonic, CEO of RIVR. "Our partnership with Veho is a major milestone on that journey to bring our technology to the U.S. As a leading parcel delivery platform in the U.S., Veho offers the ideal environment for deploying at scale—helping us deliver not just faster and more cost-effective service, but a smarter, more human-centered model for robotics in logistics."
RIVR has solved the last-100 yard challenge with the combination of its wheeled-legged design and physical AI, which enables the robot to navigate real-world obstacles like stairs, gates, and uneven terrain—all the way to the consumer's doorstep. Unlike sidewalk robots, which are limited to curbside, attended deliveries with low throughput, RIVR's robot operates in parallel with human drivers and at a speed that makes dense, multi-drop delivery commercially viable. And while drones offer reach in rural areas, RIVR is purpose-built for the complexity and scale of urban logistics—bringing automation to the final few meters of every delivery.
About VehoVeho is a next-generation parcel delivery platform, turning shipping from a cost center into a value driver. By combining purpose-built technology, customer experience obsession, and a scalable delivery network, Veho enables brands to offer an Amazon-level delivery experience that improves their bottom line. The industry-leading results speak for themselves: 99% on-time delivery, 4.9/5 customer satisfaction score, 71% fewer delivery-related refunds, and a 41% increase in customer lifetime value. Now one of America's largest tech-enabled logistics platforms, Veho serves over 113 million Americans across 50 markets–and growing. Learn why leading brands like Sephora, Lululemon, Saks, and Macy's trust Veho to increase the return on their shipping spend at shipveho.com.
About RIVRRIVR is pioneering the future of last-mile delivery with its wheeled-leg robots powered by Physical AI, giving 1 human the power of 1,000 robots. RIVR enhances efficiency, sustainability, and scalability in last-mile and last-100-yard delivery—the catalyst for 1M+ robots that unlock a data flywheel for General Physical AI. Founded in 2024 by Physical AI experts from ETH Zürich, RIVR has been at the forefront of AI-driven robotics. Their innovations have gained global recognition, gaining significant media attention with more than 100M views. RIVR is backed by Jeff Bezos through Bezos Expeditions and HSG.
Media Contacts:Veho: Evan.Wagner@shipveho.com; veho@launchsquad.comRIVR: Ben.Simmen@rivr.ai
View original content to download multimedia:https://www.prnewswire.com/news-releases/veho-and-rivr-partner-to-improve-e-commerce-delivery-through-ai-powered-robots-302466021.html
SOURCE Veho
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Corrao Group Launches MyFirst TPM™
Affordable, Scalable, and Faster-To-Deploy Trade Promotion Management (TPM) Solution SAN DIEGO, June 3, 2025 /PRNewswire/ -- Corrao Group, a global leader in Salesforce Consumer Goods Cloud implementations, today announced the official launch of MyFirst TPM™. MyFirst TPM™ is an entry-point implementation exclusively leveraging Salesforce TPM to enable fast-growing CPG brands that need structure, speed, and scalability—without a 12-month build or a massive price tag. Trade Promotion Management is a critical capability for consumer goods companies, allowing them to plan, execute, and measure promotions that drive volume and influence shopper behavior. According to research, trade spend often accounts for up to 20% of annual revenue, so the ability to track ROI and optimize performance is essential. However, traditional TPM system implementations have been costly, complex, and time-consuming, making them out of reach for many fast-growing brands. MyFirst TPM™ was designed to solve this by offering a streamlined, scalable, and more affordable path to TPM success on Salesforce. "Emerging consumer goods companies need fast, effective ways to deploy trade promotion management solutions so they can effectively manage trade programs that capture increasingly price-sensitive consumers," said Achyut Jajoo, SVP and GM, Manufacturing, Automotive, & Consumer Goods at Salesforce. "Corrao Group's MyFirst TPM™ is a fast, value-driven, and proven solution for deploying Salesforce's Trade Promotion Management technology tailored to each brand's needs. It harnesses the AI, data and industry-specific innovation from Consumer Goods Cloud to give brands the ability to build effective trade plans, optimize spend, and fuel more profitable growth." Why MyFirst TPM™ Matters For years, consumer goods and retail customers have encountered a similar challenge: they want a TPM tool but quickly turn away from traditional deployments' price, timeline, and complexity. MyFirst TPM™ aims to solve this by offering: Affordable Entry Point: Core Salesforce TPM capabilities at a fraction of the cost. Accelerated Deployment: Delivered in just five months. Right-Sized Functionality: Standardized features designed to meet common CPG planning needs. Future-Ready Architecture: Built to scale as customers grow into more advanced trade promotion strategies. AI-Enabled Insights: Post-promotion analysis and insights, helping brands make smarter, faster decisions. "Corrao Group is pleased to announce the official launch of MyFirst TPM™, the inaugural solution in our new MyFirst Family of offerings. MyFirst TPM™ empowers emerging consumer goods brands with a rapid, cost-effective, and scalable path to adopt Salesforce's comprehensive trade promotion management application. This solution is built to meet companies at their current stage and seamlessly support their growth into the future. With MyFirst TPM™, we are opening a new chapter in how we help fast-growing brands accelerate their digital transformation and achieve operational excellence," said Jack Corrao II, Managing Partner of Corrao Group. About Corrao Group Since 2008, Corrao Group has been a trusted global Salesforce partner, helping B2B organizations across retail, consumer goods, manufacturing, and healthcare drive digital transformation. Our expertise spans Salesforce Consumer Goods Cloud for Sales & Service, Retail Execution (REx), Customer Planning & Forecasting (CPF), Trade Promotion Management (TPM), Agentforce, and Data Cloud. With seamless integration and a deep understanding of industry challenges, we translate complex business processes into scalable, high-performing Salesforce solutions. As power users and implementation experts, we optimize operations, enhance decision-making, and accelerate growth—ensuring your business stays ahead in a competitive market. Please visit to learn more. Additional Resources Follow Corrao Groupon LinkedIn and X Follow Salesforce on LinkedIn and X Contact: Jack Corrao III, jcorraoiii@ View original content: SOURCE Corrao Group
Yahoo
an hour ago
- Yahoo
Mokwheel Issues Recall Notice for Scoria and Basalt-ST E-Bike Batteries Due to Labeling Discrepancy
LOS ANGELES, June 3, 2025 /PRNewswire/ -- Mokwheel, a leading provider of electric mobility solutions, is announcing a voluntary recall of select Scoria and Basalt-ST e-bike batteries due to a labeling discrepancy affecting compliance with UL Solutions standards. The recall impacts specific units sold during April and May 2024. Affected Models and Time Periods Scoria Purchase Period: April 2024Battery Serial Numbers: YXA1B0590A010150200 to YXA1B0590A010150399Vehicle Serial Numbers: BBWS4B0401 to BBWS4B0600 Basalt-ST Purchase Period: May 2024Battery Batch Number: SCA1B01010152N\\\\\\Vehicle Serial Numbers: BBWL3H0001 to BBWL3H0150 Reason for Recall The affected batteries were manufactured prior to the finalization of UL certification. As such, these batteries are not officially recognized by UL Solutions as certified. While no immediate safety issues have been reported, Mokwheel is proactively issuing a free replacement to ensure compliance and customer peace of mind. How to Identify an Affected Battery Customers who purchased a Scoria or Basalt-ST model within the specified time frames are encouraged to check their battery's serial number. If the number falls within the listed ranges above, the battery is eligible for a free replacement. Next Steps for Customers If your battery is among the affected batches: Please contact Mokwheel's support team to initiate a no-cost battery staff is available to assist with verification and coordinate the replacement process to minimize any inconvenience. Mokwheel deeply regrets any inconvenience caused and remains steadfast in its commitment to safety, compliance, and customer satisfaction. We thank our valued customers for their continued trust in our brand. View original content: SOURCE Mokwheel Bikes Inc Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Essential Thrombocythemia Market to Witness Robust Growth During the Forecast Period (2025-2034) Amid Rising R&D Activity
Beyond PEGASYS, the essential thrombocythemia treatment landscape is evolving with several promising assets in the pipeline. These include BESREMi (ropeginterferon alfa-2b), Bomedemstat (MK-3543/IMG-7289), Pelabresib (CPI-0610), Dencatistat (STP 938), INCA033989, and VAC85135. LAS VEGAS, June 3, 2025 /PRNewswire/ -- Essential thrombocythemia is a chronic form of myeloproliferative neoplasm (MPN) marked by an abnormally high platelet count in the bloodstream. It is most frequently diagnosed in women over 50 and involves the excessive production of platelet precursors in the bone marrow. Common complications include blood clots and bleeding, while less frequent but more serious outcomes in advanced stages can involve progression to myelofibrosis or acute leukemia. As of 2024, approximately 167K individuals in the US were diagnosed with essential thrombocythemia, with about 75% of these cases linked to mutations in the JAK2 gene. During the same year, an estimated 85K patients in the US received first-line treatment for essential thrombocythemia. The primary goal of essential thrombocythemia management is to reduce the risk of vascular complications, such as thrombotic and hemorrhagic events, which are major contributors to illness and death. Treatment approaches are guided by a risk stratification system that classifies patients as either low or high risk for thrombosis. Typically, low-risk individuals are younger and have no history of clotting events, while high-risk patients are generally over 60 years old and have experienced thrombosis in the past. Learn more about the essential thrombocythemia cancer @ New Treatment for Essential Thrombocythemia For low-risk patients, aspirin is recommended, provided there are no major contraindications. However, caution is advised when platelet counts exceed 1,000 × 10⁹/L, as this raises the risk of acquired von Willebrand disease. In such cases, if laboratory findings suggest von Willebrand abnormalities, aspirin should be avoided. Aspirin is also the preferred treatment in patients experiencing microvascular complications like erythromelalgia. In contrast, high-risk patients are typically managed with a combination of antiplatelet and cytoreductive therapies. Hydroxyurea is generally considered the first-line agent for cytoreduction. However, anagrelide may be used as an alternative when hydroxyurea is poorly tolerated or ineffective. At present, only one drug is officially approved for the treatment of essential thrombocythemia, and its use is restricted to Europe. There are currently no FDA-approved therapies for essential thrombocythemia in the United States. PEGASYS, a Type I interferon, is made by pegylating interferon alfa-2a, which involves attaching polyethylene glycol (PEG) chains to the molecule. Find out more on FDA-approved essential thrombocythemia drugs @ Essential Thrombocythemia Treatment Options PEGASYS was previously approved by the European Commission (EC) for treating Chronic Hepatitis B in adults and children over 3, and Chronic Hepatitis C in adults and children over 5, in combination with other medications. In August 2024, pharmaand GmbH announced that the EC had granted a Type II variation approval for PEGASYS, allowing its use as a monotherapy for adults with essential thrombocythemia. Various key players are leading the treatment landscape of essential thrombocythemia, such as pharma&, AOP Orphan Pharmaceuticals AG, Merck Sharp and Dohme, Novartis, Incyte Corporation, and others. Discover which therapies are expected to grab major essential thrombocythemia market share @ Essential Thrombocythemia Market Report Bomedemstat (MK-3543) is an experimental small-molecule drug developed by Merck that irreversibly inhibits LSD1, a key regulator of hematopoietic stem cell proliferation, differentiation, and maturation. The drug is under clinical evaluation for various myeloproliferative neoplasms (MPNs), including essential thrombocythemia, myelofibrosis, and polycythemia vera. In 2018, Bomedemstat was granted Orphan Drug Designation (ODD) for essential thrombocythemia treatment. In January 2020, Imago BioSciences received Fast Track Designation (FTD) from the US FDA for bomedemstat for the same indication. By November 2022, Merck announced its acquisition of Imago BioSciences, a clinical-stage biotechnology company focused on bomedemstat for myelofibrosis treatment, for $36 per share in cash, totaling approximately $1.35 billion. This strategic move aimed to strengthen Merck's hematology portfolio and establish its presence in the growing myelofibrosis market. PharmaEssentia is advancing ropeginterferon alfa-2b (P1101) for essential thrombocythemia, offering a biweekly injection regimen aimed at improving tolerability and patient adherence, thereby enhancing therapeutic outcomes. A global Phase III clinical trial for essential thrombocythemia is currently in progress. Participants who respond positively during the initial study period will continue into an extension phase for long-term evaluation. Pelabresib, another investigational therapy, is a selective small molecule targeting BET (bromodomain and extra-terminal domain) proteins, which are involved in gene regulation associated with hematologic malignancies. The ongoing Phase II MANIFEST trial (NCT02158858) is assessing its efficacy in patients with myelofibrosis and high-risk ET through an open-label study. In February 2024, MorphoSys entered into a Business Combination Agreement with Novartis AG, reflecting Novartis's plan to launch a voluntary public takeover offer for all outstanding MorphoSys bearer shares without nominal value. Discover more about drugs for essential thrombocythemia in development @ Essential Thrombocythemia Clinical Trials The anticipated launch of these emerging therapies for essential thrombocythemia are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the essential thrombocythemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for essential thrombocythemia is expected to grow from USD 417 million in the 7MM in 2024 at a significant CAGR by 2034. The market size of essential thrombocythemia is expected to grow due to several factors, including an increase in the prevalent pool, the expected entry of emerging therapies with novel targets, and attractive pricing in the 7MM. DelveInsight's latest published market report, titled as Essential Thrombocythemia Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the essential thrombocythemia country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The essential thrombocythemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases Symptom-specific Cases Gender-specific Cases Mutation-specific Cases Risk-specific Cases Age-specific Cases Total Treated Cases The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM essential thrombocythemia market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this essential thrombocythemia market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the essential thrombocythemia market. Also, stay abreast of the mitigating factors to improve your market position in the essential thrombocythemia therapeutic space. Related Reports Essential Thrombocythemia Epidemiology Essential Thrombocythemia Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the essential thrombocythemia epidemiology trends. Essential Thrombocythemia Pipeline Essential Thrombocythemia Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key essential thrombocythemia companies, including PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals, among others. Polycythemia Vera Market Polycythemia Vera Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key polycythemia vera companies, including IIncyte, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience, Disc Medicine, GluBio Therapeutics, among others. Polycythemia Vera Pipeline Polycythemia Vera Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key polycythemia vera companies, including Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, Perseus Proteomics, Agios Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP
